Soligenix Inc. (Nasdaq: SNGX) will present results from its ricin toxin vaccine development program at the 20th Annual Conference on Vaccine Research on April 25. Shares of the biopharmaceutical leaped $1.12 to close at $3.69.
Soligenix to present data
April 19, 2017 at 17:11 PM EDT
